US Patent 9,884,058: Scope, Claims, Expiration, and Arimoclomol Patent Landscape
US Patent 9,884,058 protects methods of treating lipid storage disorders by administering hydroxylamine derivatives that increase intracellular Hsp70 through amplified Hsp70 gene expression. Its most commercially relevant species claim covers arimoclomol, the active ingredient in Miplyffa, approved by the FDA in 2024 for Niemann-Pick disease type C in combination with miglustat. The patent is a method-of-use asset, not a composition-of-matter patent, and its practical value depends on proof that an accused product is used for a covered lipid storage disorder and operates through the claimed Hsp70 mechanism. [1, 3, 4]
What does US Patent 9,884,058 protect?
The patent protects a therapeutic method with four required elements:
- Treatment of an individual with a lipid storage disorder.
- Administration of a bioactive agent that increases intracellular Hsp70.
- Hsp70 increase through amplification of Hsp70 gene expression.
- The agent must be a hydroxylamine derivative.
Claim 1 is the independent claim. Claims 2 through 13 narrow the method by adding therapeutic purpose, specific compounds, disease classes, combination treatments, enzyme replacement therapies, and recombinant Hsp70 products.
| Claim group |
Subject matter |
Commercial significance |
| Claim 1 |
Hydroxylamine derivative for lipidosis through Hsp70 gene-expression amplification |
Broadest method claim |
| Claim 2 |
Curative or ameliorating treatment |
Adds treatment objective |
| Claims 3-6 |
Bimoclomol, arimoclomol, BRX-220, BRX-345 and BGP-15 |
Defines the principal chemical species |
| Claim 7 |
Sphingolipidosis |
Targets diseases including Niemann-Pick and related disorders |
| Claims 8-10 |
Combination therapy, including ERT |
Relevant to combination regimens |
| Claim 11 |
Imiglucerase, miglustat, agalsidase beta or agalsidase alpha |
Names specific companion treatments |
| Claims 12-13 |
Hsp70 fragments, variants and recombinant Hsp70 |
Covers protein-combination approaches |
The most important claim for arimoclomol is claim 5. The most important claim for Niemann-Pick disease type C is claim 7, read together with claims 1 and 5. Claim 10 is commercially relevant to products administered with enzyme replacement therapy, although Miplyffa’s FDA-approved regimen uses miglustat rather than an enzyme replacement product. [1, 3]
How broad is claim 1 of US 9,884,058?
Claim 1 is broad in disease scope but narrower in mechanism and chemistry.
The term “lipid storage disorder” can encompass disorders in which lipids or lipid-derived materials accumulate in cells. Claim 7 narrows that field to sphingolipidoses. The patent therefore reaches beyond Niemann-Pick disease type C on its face and can cover other sphingolipid storage diseases if the remaining limitations are satisfied.
The chemical limitation is important. The claim does not cover every Hsp70 inducer. The accused agent must be a hydroxylamine derivative. A small-molecule product that increases Hsp70 through another chemical class would fall outside the literal chemical limitation, even if it produces the same biological result.
The mechanism limitation is also material. The agent must increase intracellular Hsp70 by amplifying Hsp70 gene expression. Evidence of Hsp70 protein elevation alone may not establish infringement if the increase results from protein stabilization, reduced degradation, altered translation, or another pathway rather than gene-expression amplification.
Key claim-construction issues
| Limitation |
Scope issue |
| “Capable of increasing” |
May require only the capability to produce the claimed effect, but the product’s mechanism must still be supported by evidence |
| “Amplifying Hsp70 gene expression” |
Creates a mechanistic limitation that may require molecular and pharmacology evidence |
| “Hydroxylamine derivative” |
Chemical-class boundary may be contested for analogues and salts |
| “Lipid storage disorder” |
Broad disease category, potentially subject to written-description and enablement challenges |
| “Individual in need thereof” |
Requires a treatment context and a patient with the claimed disorder |
| “Curative or ameliorating” |
Claim 2 is narrower and likely satisfied by disease-symptom or disease-progression improvement |
Which claims cover arimoclomol and Miplyffa?
Claims 3, 4 and 5 expressly cover arimoclomol. Claim 5 is the strongest product-specific method claim because it removes ambiguity created by the broader “hydroxylamine derivative” language.
Miplyffa is arimoclomol, marketed by Zevra Therapeutics. The FDA approved Miplyffa capsules on September 20, 2024, for the treatment of neurological manifestations of Niemann-Pick disease type C in patients aged 2 years and older, in combination with miglustat. [3, 4]
The FDA-approved regimen creates a direct mapping to the patent:
| Miplyffa element |
Patent relationship |
| Arimoclomol |
Expressly covered by claims 4 and 5 |
| Niemann-Pick disease type C |
A sphingolipid storage disorder for purposes of claim 7 |
| Miglustat combination |
Expressly identified in claim 11 |
| Disease treatment |
Satisfies the treatment element in claim 1 |
| Hsp70-inducing mechanism |
Central factual requirement under claim 1 |
Claim 11 describes miglustat within a list introduced as “enzyme replacement therapy.” Miglustat is generally characterized pharmacologically as a substrate reduction therapy, not an enzyme replacement therapy. The drafting error does not necessarily remove miglustat from the claim because the claim expressly names the compound. It can, however, create claim-construction issues concerning the relationship between the introductory phrase and the listed alternatives.
What diseases and therapies are covered?
The patent’s disease scope is broader than the current FDA indication for Miplyffa.
Disease categories
The claims potentially reach:
- Niemann-Pick disease type C
- Niemann-Pick disease types A and B, subject to the claim limitations
- Gaucher disease
- Fabry disease
- Krabbe disease
- metachromatic leukodystrophy
- other sphingolipidoses
- broader lipid storage disorders supported by the patent’s disclosure
The claims do not automatically cover every treatment of these diseases. The administered product must be a hydroxylamine derivative and must satisfy the Hsp70 gene-expression limitation.
Combination therapy
Claims 8 through 11 cover combination use with:
- enzyme replacement therapy
- pain relievers
- corticosteroids
- transplantation
- substrate reduction therapy
- Hsp70 protein
- Hsp70 fragments or variants
- recombinant Hsp70
The named ERT products are imiglucerase, agalsidase beta and agalsidase alpha. Miglustat is separately relevant as a substrate-reduction agent, notwithstanding the claim’s grouping language.
When does US Patent 9,884,058 lose exclusivity?
The patent’s nominal term runs to approximately November 2029, based on the underlying priority and filing chronology reflected in the patent record. The enforceable expiration date should be taken from the USPTO patent-term record and any FDA Orange Book listing because patent term adjustment can alter the statutory end date. [1, 2]
| Exclusivity right |
Relevance to arimoclomol |
| US 9,884,058 patent |
Method-of-use protection through approximately November 2029, subject to term adjustment |
| FDA orphan-drug exclusivity |
Miplyffa received orphan designation for Niemann-Pick disease type C; orphan exclusivity generally runs seven years from approval for the protected indication |
| FDA new-chemical-entity exclusivity |
May apply if the statutory NCE requirements are satisfied; it is separate from patent protection |
| Pediatric exclusivity |
No conclusion should be drawn without an applicable FDA pediatric exclusivity entry |
The patent and regulatory exclusivity periods do not necessarily end on the same date. Orphan exclusivity can block FDA approval of the same drug for the same disease or indication even after a patent expires. It does not generally block approval of a different drug or a different indication.
What is the Orange Book status of arimoclomol?
Miplyffa is an FDA-approved prescription product and is subject to Orange Book patent and exclusivity listings. The relevant patent question is whether US 9,884,058 is listed against the approved arimoclomol product and the specific FDA-approved use. Orange Book listing practice for method-of-use patents requires a reasonable relationship between the patent claims and the approved labeling. [2]
The commercial impact is strongest where:
- the proposed generic labeling includes Niemann-Pick disease type C;
- the proposed product is arimoclomol;
- the label directs use with miglustat;
- the patent is listed against the NDA; and
- the patent remains enforceable.
A generic applicant may attempt a section viii “skinny label” strategy by carving out the patented indication. That strategy would be difficult if the only commercially meaningful use of arimoclomol is the patented Niemann-Pick indication. It would be more viable if an unpatented indication or use supported a substantial market.
Which companies are challenging US 9,884,058?
No publicly established Paragraph IV litigation involving an ANDA challenger to arimoclomol and US 9,884,058 was identified in the available FDA and federal-court records through the early commercial period following Miplyffa’s approval. Miplyffa’s recent approval, orphan status and specialized patient population reduce the immediate probability of conventional generic entry.
The relevant challenger scenarios are:
| Scenario |
Risk level |
Rationale |
| ANDA with Paragraph IV challenge |
Low near term |
Limited market size and recent approval |
| ANDA with section viii carve-out |
Moderate in theory |
Depends on nonpatented uses and labeling design |
| 505(b)(2) product |
Moderate |
Could challenge method coverage or rely on alternative labeling |
| Off-label use of arimoclomol |
Commercially relevant |
May create inducement or contributory-infringement issues |
| Biosimilar challenge |
Not applicable |
Arimoclomol is a small molecule, not a biologic |
| Competing non-hydroxylamine Hsp70 activator |
Outside literal claim 1 if mechanism and chemistry differ |
May still face other patent or regulatory barriers |
How strong is the patent estate?
US 9,884,058 is strongest against arimoclomol use for Niemann-Pick disease type C, especially where the accused labeling or promotional material directs administration with miglustat.
Its principal strengths are:
- express recitation of arimoclomol in claim 5;
- express coverage of sphingolipidosis in claim 7;
- express recitation of miglustat in claim 11;
- alignment between the claims and the FDA-approved Miplyffa regimen;
- method claims that can reach treatment conduct even if composition patents have expired.
Its principal vulnerabilities are:
- the need to prove Hsp70 gene-expression amplification;
- potential disputes over the meaning of “hydroxylamine derivative”;
- broad disease-category language;
- potential written-description and enablement challenges for the full lipid-storage-disorder genus;
- possible noninfringement based on a different mechanism of Hsp70 elevation;
- possible label-carveout strategies.
The patent is materially stronger as an arimoclomol/Niemann-Pick method patent than as a broad platform patent covering all Hsp70-based lipid-storage therapies.
What patent litigation and settlement risks exist?
A Paragraph IV case would likely focus on three issues:
- Whether the proposed product is directed to a patented use.
- Whether arimoclomol increases Hsp70 through amplification of gene expression.
- Whether the relevant patent claims are valid and enforceable.
A generic applicant could challenge validity under anticipation, obviousness, written description, enablement and indefiniteness theories. The strongest noninfringement position would likely be that the applicant’s label omits Niemann-Pick disease type C or that the product’s Hsp70 effect does not result from amplified gene expression.
No publicly reported settlement agreement involving a generic challenger and US 9,884,058 was identified in the available record. The most probable commercial resolution, if a challenge emerges, would depend on the remaining patent term, orphan-exclusivity date, patient-population size and the strength of mechanism evidence.
How does US 9,884,058 compare with competing disease and Hsp70 programs?
| Product or program |
Modality |
Relationship to US 9,884,058 |
| Miplyffa/arimoclomol |
Hydroxylamine derivative |
Directly targeted by claims 4 and 5 |
| Miglustat |
Substrate reduction therapy |
Expressly named in claim 11 as a combination agent |
| Enzyme replacement therapies |
Biologic proteins |
Covered only as combination partners in claims 8-11 |
| Adrabetadex/VTS-270 |
Cyclodextrin-based investigational therapy |
Chemical class differs from the claimed hydroxylamine derivatives |
| Non-hydroxylamine Hsp70 activators |
Small molecules or biologics |
Potentially outside literal claim 1 |
| Recombinant Hsp70 |
Protein therapy |
Addressed in claims 9, 12 and 13 as a combination treatment |
There is no biosimilar pathway for arimoclomol. A competing product would generally proceed through an abbreviated new drug application, a 505(b)(2) application, or a full NDA, depending on its active ingredient, formulation and reliance on Miplyffa’s clinical data.
What manufacturing and geographic barriers remain?
The patent is not principally a manufacturing patent. It does not, based on the supplied claims, protect:
- a specific arimoclomol synthesis;
- a particular salt or polymorph;
- a capsule formulation;
- a manufacturing process;
- a particle-size specification;
- a release profile; or
- a specific pharmaceutical composition.
The claims are method claims, so they can create commercial exposure in the United States without preventing manufacture of arimoclomol outside the United States. US infringement risk arises from making, using, offering for sale, selling or importing a product connected to the patented method under the Patent Act.
Foreign protection must be assessed country by country. A US patent does not create European, Asian or other territorial rights. The relevant international family members, national-phase grants, local expiration dates and local regulatory exclusivities must be reviewed separately.
Key Takeaways
- US 9,884,058 is a method-of-use patent covering hydroxylamine derivatives that increase intracellular Hsp70 through amplified Hsp70 gene expression.
- Claims 4 and 5 expressly cover arimoclomol.
- Claim 7 reaches sphingolipidoses, including the disease category relevant to Niemann-Pick disease type C.
- Claim 11 expressly names miglustat, despite grouping it under an enzyme-replacement heading.
- The patent’s nominal expiration is approximately November 2029, subject to USPTO term adjustment and any applicable extension.
- Miplyffa’s FDA-approved arimoclomol/miglustat regimen closely corresponds to the patent claims.
- The patent is not a biosimilar barrier and does not principally protect formulation or manufacturing technology.
- The main litigation vulnerability is the requirement to prove Hsp70 gene-expression amplification.
- No publicly established Paragraph IV challenge or settlement involving this patent was identified in the available record.
- The patent is strongest as targeted protection for arimoclomol treatment of Niemann-Pick disease type C, rather than as an unrestricted Hsp70 platform patent.
FAQs About US Patent 9,884,058 and Arimoclomol
Does US 9,884,058 cover arimoclomol itself?
No. It covers methods of using arimoclomol. The supplied claims do not claim arimoclomol as a standalone chemical composition.
Does the patent cover Miplyffa used without miglustat?
Claims 1, 5 and 7 do not require miglustat. Claims 8 through 11 address combination treatment. Miplyffa monotherapy can therefore fall within the independent arimoclomol treatment claims if the other limitations are met.
Can a generic arimoclomol applicant avoid the patent by removing Niemann-Pick disease from its label?
Potentially, through a section viii labeling carve-out, but the strategy depends on whether a commercially meaningful noninfringing indication exists and whether the FDA-approved label can omit the patented use.
Is arimoclomol subject to biosimilar competition?
No. Arimoclomol is a small-molecule drug. Any abbreviated competition would generally involve an ANDA rather than a biosimilar application.
Does the patent cover all Hsp70-inducing medicines?
No. The claims require a hydroxylamine derivative and an Hsp70 increase achieved through amplification of Hsp70 gene expression. A non-hydroxylamine agent or a product operating through a different Hsp70 mechanism may fall outside the literal scope.
References
- United States Patent and Trademark Office. (2018). United States Patent No. 9,884,058: Use of hydroxylamine derivatives for the treatment of lipid storage disorders.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Miplyffa (arimoclomol) prescribing information.
- U.S. Food and Drug Administration. (2024, September 20). FDA approves first treatment for Niemann-Pick disease type C.
- U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension records.
